retatrutide ly3437943 triple agonist glp-1 gip glucagon Eli Lilly just announced striking Phase 3 results for retatrutide, an experimental “triple agonist” that acts on three gut-hormone targets at once. On the top dose, people lost an average of 28% LY3437943, a novel triple glucagon,

Weight management issues are common in women dealing with conditions like menopause, PCOS or endometriosis

Concerns about delayed treatment Dr

Weight Loss Rates and Timelines One of the most common questions among couples or friends considering Retatrutide together is who will see results first

Most common side effects are usually mild to moderate and tend to resolve on their own

Short-term use of adjunct medications like proton pump inhibitors and H2-antagonists for reflux, or cyclizine for nausea, can be beneficial

Retatrutide is currently an investigational medication undergoing clinical trials, and regulatory approval status may vary by country